8.85

1.61% 0.14

After Hours: 8.84 -0.010 -0.11%

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Financials Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is traded at $8.85, with a volume of 1.20M. It is up +1.61% in the last 24 hours and up +25.53% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Previous Close:

$8.71

Open:

$8.75

24h Volume:

1.20M

Relative Volume:

0.99

Market Cap:

$1.25B

Revenue:

$175.51M

Net Income/Loss:

$-78.02M

P/E Ratio:

-16.70

EPS:

-0.53

Net Cash Flow:

$-34.18M

1W Performance:

+7.40%

1M Performance:

+25.53%

6M Performance:

+69.87%

1Y Performance:

+3.63%

1-Day Range:

$8.70

$8.91

1-Week Range:

$8.30

$9.04

52-Week Range:

$4.71

$9.74

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

250-744-2487

Address

#140, 14315 - 118 AVENUE, EDMONTON, BC

Employee

300

Twitter

@AuriniaPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUPH Aurinia Pharmaceuticals Inc	8.85	1.25B	175.51M	-78.02M	-34.18M	-0.53
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

Nov 25, 2024

Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Nov 25, 2024

Nov 22, 2024

Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace

Nov 22, 2024

Nov 20, 2024

Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - MSN

Nov 20, 2024

Nov 18, 2024

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise

Nov 18, 2024

Nov 17, 2024

(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 17, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat

Nov 17, 2024

Nov 15, 2024

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise

Nov 15, 2024

Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Aurinia to Participate in Jefferies London Healthcare Conference - sharewise

Nov 14, 2024

Aurinia Pharmaceuticals Engages at London Conference - TipRanks

Nov 14, 2024

Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock - Investing.com India

Nov 14, 2024

Nov 13, 2024

Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock By Investing.com - Investing.com Nigeria

Nov 13, 2024

Nov 12, 2024

Aurinia Pharmaceuticals director sells shares valued at $38,415 - Investing.com India

Nov 12, 2024

Aurinia Pharmaceuticals director sells shares valued at $38,415 By Investing.com - Investing.com Canada

Nov 12, 2024

Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com - Defense World

Nov 12, 2024

Aurinia Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 12, 2024

Nov 11, 2024

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH) - Seeking Alpha

Nov 08, 2024

Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - Pharmaceutical Technology

Nov 08, 2024

Nov 07, 2024

Earnings call: Aurinia Pharmaceuticals announced a 24% increase in total net revenue - Investing.com

Nov 07, 2024